Violetta Hughes was appointed the Company's Chief Accounting Officer, effective September 1, 2025, becoming the Company's principal accounting officer (replacing Jason K. Garland in that capacity, while Mr. Garland continues as CFO). She is a seasoned finance executive with deep expertise in financial controllership, operational finance, and global team leadership across life sciences, medical technology and pharmaceuticals, bringing over 25 years of experience.
From January 2023 to August 2025, Ms. Hughes served as VP and Chief Accounting Officer at Azenta, Inc. (NASDAQ: AZTA). From December 2020 to December 2022, she served as SVP and Chief Accounting Officer at Akebia Therapeutics, Inc. (NASDAQ: AKBA). Prior to AKBA, from December 2016 to November 2020, she served as SVP of Accounting, Corporate Controller at AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), until its acquisition by Covis Pharma in November 2020.
Ms. Hughes holds a B.S. in Accounting from the University of Massachusetts Lowell.
Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.